This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.

NCT07570888 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Fibrosis
Interstitial Lung Disease (ILD)

Interventions

DRUG: Nerandomilast 18 mg - adult formulation

Sponsor

University of British Columbia

Collaborators

[object Object]